Clinical Trial

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Name: WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) — clinical trial record (NCT06967805)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

Protocol Amendment History 2 changes

notable Trial sites expanded: 65 -> 69 locations 2026-05-07

notable Trial sites expanded: 44 -> 65 locations 2026-03-31

Trial Details

NCT Number	NCT06967805
Lead Sponsor	Mediar Therapeutics
Conditions	Idiopathic Pulmonary Fibrosis
Enrollment	164 participants
Start Date	2025-05-05
Primary Completion	2027-08 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-10